scholarly journals Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein

2002 ◽  
Vol 39 (4) ◽  
pp. 404-405 ◽  
Author(s):  
Franca Pagani ◽  
Roberto Bonora ◽  
Graziella Bonetti ◽  
Mauro Panteghini
Keyword(s):  
Fatty Acid ◽  
Immunosorbent Assay ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Characteristic Curve ◽  
Enzyme Linked Immunosorbent Assay ◽  
Fatty Acid Binding ◽  
Reference Limit ◽  
Acid Binding Protein ◽  
Upper Reference Limit

Background: We evaluated the sandwich enzyme-linked immunosorbent assay (ELISA) MARKIT®-M for the determination of heart fatty-acid-binding protein (H-FABP). Results and Conclusions: The between-run coefficient of variation of this assay was <3·9 and it showed good correlation with a previously established ELISA method. The upper reference limit in 30 healthy individuals was 6·1 μg/L. Admission serum H-FABP was evaluated against myoglobin in 41 patients with suspected myocardial infarction (onset of symptoms ≤ 5 h). H-FABP showed the same diagnostic efficiency as myoglobin [area (standard error) under the receiver operating characteristic curve: 0·798 (0·079) for H-FABP, 0·771 (0·085) for myoglobin, P = 0·55]. However, using the upper reference limit as decision cut-off, the sensitivity for H-FABP [91%; 95% confidence interval (CI): 76-98%] was significantly ( P = 0·019) higher than that of myoglobin (65%; 95% CI: 47-80%).

scholarly journals Epidermal Fatty Acid-Binding Protein: A Novel Marker in the Diagnosis of Dry Eye Disease in Sjögren Syndrome

2018 ◽  
Vol 19 (11) ◽  
pp. 3463 ◽  
Author(s):  
Megumi Shinzawa ◽  
Murat Dogru ◽  
Seika Den ◽  
Takehiro Ichijima ◽  
Kazunari Higa ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Dry Eye ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Sjögren Syndrome ◽  
Enzyme Linked Immunosorbent Assay ◽  
Sjogren Syndrome ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Healthy Control

Purpose: Sjögren syndrome (SS) is a chronic inflammatory autoimmune disease of the lacrimal and salivary glands. This study compared the concentrations of epidermal fatty-acid binding protein (E-FABP) in the saliva, serum, and tears of SS patients with dry eye and dry mouth, with those of healthy adults to investigate the usefulness of E-FABP as a diagnostic marker for SS. Design: Prospective, observational case series. Participants: The subjects were 11 new patients with untreated Sjogren syndrome and 12 healthy control individuals. Methods: The diagnosis of SS was in accordance with the Ministry of Health, Labour and Welfare (Japan) Diagnostic Criteria (1999). Saliva, serum, and tear specimens were collected during internal medicine, dental, and ophthalmological examinations. The ophthalmological tests included the Dry Eye-related Quality of life Score (DEQS), tear break-up time (BUT), vital staining with fluorescein (FS) and lissamine green (LG), and the Schirmer test-1. The E-FABP concentration in the tears, saliva, and serum was measured by enzyme-linked immunosorbent assay (ELISA). Main outcome measure: The E-FABP concentrations were compared between patients and controls. Results: There were significant differences between the patient and healthy control groups in all ophthalmological test results. There were no significant differences between the groups in the E-FABP concentrations in the saliva (p = 0.1513) or the serum (p = 0.4799), but the E-FABP concentration in the tears significantly differed between groups. The E-FABP concentration in tears tended to be significantly lower in patients with SS (mean, 323.5 ± 325.6 pg/mL) than healthy control subjects (mean, 4076 pg/mL; p = 0.0136). The E-FABP concentration in tears significantly correlated with the results of dry eye parameters. Conclusion: The E-FABP concentration in tears appears to be related to ocular surface epithelial damage and tear stability and may be a promising novel biomarker in the diagnosis of SS.

Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease

2016 ◽  
Vol 54 (10) ◽  
Author(s):  
Atsuko Kamijo-Ikemori ◽  
Takeshi Sugaya ◽  
Maki Yoshida ◽  
Seiko Hoshino ◽  
Satoshi Akatsu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Clinical Utility ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Assay Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

AbstractBackground:Urinary liver-type fatty acid binding protein (L-FABP) measured by enzyme-linked immunosorbent assay method (ELISA) was approved as a clinical biomarker of tubular damage by the Japanese Ministry of Health, Labor and Welfare (MHLW) in 2011. We evaluated a new latex-enhanced immunoturbidimetric assay (LTIA) to evaluate the clinical utility of urinary L-FABP measured by LTIA versus an ELISA assay.Methods:LTIA with anti-human L-FABP mouse monoclonal antibodies was performed using an automated clinical chemistry analyzer. Five positive samples with low, medium and high L-FABP concentrations were analyzed to determine the within-run precision. In patients with chronic kidney disease (CKD) (n=91), urinary L-FABP levels were measured by ELISA and LTIA.Results:Measurement of urinary L-FABP revealed urinary L-FABP levels within 30 min. The within-run coefficient of variation was 10.0% for 1.4 ng/mL, 4.4% for 2.5 ng/mL, 3.2% for 9.8 ng/mL, 1.5% for 50.1 ng/mL, and 1.2% for 102.7 ng/mL. Concentrations of urinary L-FABP measured by LTIA were significantly correlated with those measured by ELISA (ρ=0.932). Proportional systematic error was almost within limits of agreement (LOA). Urinary L-FABP levels measured by LTIA were significantly correlated with urinary albumin (ρ=0.634), urinary NAG (ρ=0.688) and eGFR (ρ=–0.561).Conclusions:Measurement of urinary L-FABP by LITA was simple, speedy, and similar in quality to ELISA results. Therefore, this method was approved as external body diagnosing medicines by the Japanese MHLW in 2014. Urinary L-FABP is expected to be widely used in various pathophysiological conditions by measuring urinary L-FABP using LTIA.

One-Step Enzyme-Linked Immunosorbent Assay (ELISA) for Plasma Fatty Acid-Binding Protein

1997 ◽  
Vol 34 (3) ◽  
pp. 263-268 ◽  
Author(s):  
K Will H Wodzig ◽  
Maurice M A L Pelsers ◽  
Ger J van der Vusse ◽  
Werner Roos ◽  
Jan F C Glatz
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Rapid Determination ◽  
Binding Protein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Fatty Acid Binding ◽  
Standard Curve ◽  
Acid Binding Protein ◽  
Sandwich Type ◽  
One Step

To allow a more rapid determination of heart-type fatty acid-binding protein (FABP) concentration in plasma a direct non-competitive (sandwich-type) ELISA was developed which uses high-affinity monoclonal antibodies to FABP. Total performance time of the one-step immunoassay is 45min. The standard curve was linear between 0·2–6μg/L, and the within-run and between-run coefficients of variations were below 6 and 11%, respectively. The serum FABP concentration measured in 79 healthy individuals was 1·6 (0·8) [mean (SD), range 0·3–5·0] μg/L. The assay can be used for rapid plasma or serum FABP measurement in the early diagnosis of acute myocardial infarction.

Diagnostic potential ofFasciola gigantica-derived 14.5 kDa fatty acid binding protein in the immunodiagnosis of bubaline fascioliasis

2012 ◽  
Vol 87 (2) ◽  
pp. 147-153 ◽  
Author(s):  
G. Allam ◽  
I.R. Bauomy ◽  
Z.M. Hemyeda ◽  
T.M. Diab ◽  
T.F. Sakran
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Sandwich Elisa ◽  
Fasciola Gigantica ◽  
Enzyme Linked Immunosorbent Assay ◽  
Diagnostic Efficacy ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Diagnostic Potential

AbstractThe 14.5 kDa fatty acid binding protein (FABP) was isolated from the crude extract of adultFasciola giganticaworms. Polyclonal anti-FABP IgG was generated in rabbits immunized with prepared FABP antigen. Sandwich enzyme-linked immunosorbent assay (ELISA) was applied to detect coproantigen in stools and circulatingFasciolaantigen (CA) in sera of 126 water buffaloes by using purified and horseradish peroxidase (HRP)-conjugated anti-FABP IgG. Sandwich ELISA sensitivity was 96.97% and 94.95%; while specificity was 94.12% and 82.35% for coproantigen and CA detection, respectively. However, sensitivity and specificity of the Kato–Katz technique was 73.74% and 100%, respectively. The diagnostic efficacy of sandwich ELISA was 96.55% and 93.1% for coproantigen and CA detection, respectively. In contrast, the diagnostic efficacy of the Kato–Katz technique was 77.59%. In conclusion, these results demonstrate that the purified 14.5 kDa FABP provides a more suitable antigen for immunodiagnosis of early and current bubaline fascioliasis by using sandwich ELISA.

scholarly journals Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Marenao Tanaka ◽  
Masato Furuhashi ◽  
Norihito Moniwa ◽  
Takuto Maeda ◽  
Hideki Takizawa ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Fatty Acid ◽  
Renal Dysfunction ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Characteristic Curve ◽  
Minimal Change ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Nephrotic Range Proteinuria

Abstract Background Fatty acid-binding protein 4 (FABP4), but not FABP1 (liver-type FABP), is ectopically induced in injured glomerular endothelial cells, and urinary FABP4 (U-FABP4) level is associated with proteinuria and renal dysfunction in a general population. Methods The clinical significance of U-FABP4 was investigated in 81 patients (male/female: 43/38, age: 57 ± 17 years) who underwent kidney biopsy. Results U-FABP4 was negatively correlated with estimated glomerular filtration rate (eGFR) (r = − 0.56, P < 0.01) and was positively correlated with age, blood pressure, triglycerides, proteinuria (r = 0.58, P < 0.01), plasma FABP4 and urinary FABP1 (U-FABP1) (r = 0.52, P < 0.01). Multivariable regression analysis showed that eGFR, proteinuria and U-FABP1 were independent predictors of U-FABP4. The level of U-FABP4, but not that of proteinuria, eGFR or U-FABP1, in minimal change nephrotic syndrome (MCNS) was significantly lower than the level in membranous nephropathy (MN) and that in diabetic nephropathy. Receiver operating characteristic curve analysis indicated that U-FABP4 level ≤ 0.78 μg/gCr predicted MCNS in patients who had nephrotic-range proteinuria with a high level of accuracy. When divided by the median value of U-FABP4 at baseline in 33 of the 81 patients who could be followed up, the yearly change (post–pre) in eGFR in the low U-FABP4 group was significantly greater than that in the high U-FABP4 group (median: 11.0 vs. -5.0 mL/min/1.73m2/year). Conclusions U-FABP4 level is independently associated with proteinuria and renal dysfunction in patients with glomerular kidney disease. A low U-FABP4 level may predict MCNS in patients with nephrotic syndrome and would be a useful biomarker for differential diagnosis of MCNS and MN, which are common causes of nephrotic syndrome.

scholarly journals Adipocyte Fatty Acid-Binding Protein 4 is Altered in Growth Discordant Dichorionic, but not in Monochorionic Twins

2019 ◽  
Vol 4 (4) ◽  
Author(s):  
Susanne Schrey-Petersen ◽  
Saskia Bäumer ◽  
Ulrike Lössner ◽  
Holger Stepan
Keyword(s):  
Fatty Acid ◽  
Birth Weight ◽  
Cord Blood ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Blood Levels ◽  
Monochorionic Twins ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Abstract Context The fetal period has a critical and long-lasting impact on the regulation of metabolic processes and a life-long predisposition for obesity and metabolic syndrome. The exact mechanisms are unknown, but epigenetic regulation likely plays a major role. Twins represent an excellent model to study these mechanisms, as they share the same intrauterine environment and similar or even the same genetic information. We examined cord blood levels of adipocyte fatty-acid binding protein 4 (A-FABP or FABP4), a novel adipokine correlated with obesity and metabolic disease in children and adults. Objective To examine A-FABP levels in the cord blood of twins with concordant and discordant growth and in singletons with intrauterine growth restriction (IUGR). Design Cohort study of 36 twin pairs (25 growth concordant and 11 growth discordant), and 42 singleton pregnancies (28 IUGR and 13 normally grown controls, 1 HELLP). Outcome Measures Cord blood A-FABP levels measured by enzyme-linked immunosorbent assay (ELISA). Results A-FABP levels were higher in the smaller of growth discordant dichorionic (DC) twins versus their co-twins (109.46 ± 62.80 ng/mL vs. 72.93 ± 36.66 ng/mL, P = 0.028). A-FABP was negatively correlated with birth weight and gestational age (P &lt; 0.001), but not with birth weight z-score (P = 0.37). Conclusions Increased A-FABP levels might be associated with an increased metabolic risk in growth-restricted (twins) and prematurely born infants.

scholarly journals Serum Fatty Acid Binding protein 5 (FABP5) as a Potential Biomarker of Inflammation in Psoriasis.

2020 ◽  
Author(s):  
Dorota Kozłowska ◽  
Hanna Myśliwiec ◽  
Ewa Harasim-Symbor ◽  
Anna Justyna Milewska ◽  
Adrian Chabowski ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Total Serum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Gas Liquid Chromatography ◽  
Metabolic Disturbances ◽  
Fatty Acid Binding ◽  
Acid Binding Protein ◽  
Potential Biomarker

Abstract Background: Psoriasis is an immune-mediated chronic inflammatory disease with cardiometabolic comorbidities. Fatty acid binding protein 5 (FABP5) is elevated in human psoriatic keratinocytes and could be potentially involved in systemic metabolic disturbances. The aim of the study was to evaluate serum FABP5 in psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband - ultraviolet B (NB-UVB). Methods: Seventy four patients with active plaque-type psoriasis and 30 healthy controls were enrolled in the study. Thirty patients were treated with NB-UVB. Patients were divided into subgroups based on their disease severity measured by Psoriasis Area and Severity Index (PASI) and Body Mass Index (BMI). The serum concentrations of FABP5 were measured using commercially available Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Total serum fatty acids content and composition was measured by gas–liquid chromatography. Results: Serum FABP5 levels in psoriatic patients (both obese and non-obese) were higher versus control group (P <0.001). FABP5 in patients with PASI >20 was higher compared to the mild group (PASI <10) (P <0.001) and serum FABP5 correlated positively with PASI score (r=0.41, P <0.001). There was also positive correlation between FABP5 and basic inflammation indices: C-reactive protein, white blood cell count and the platelet count. Decrease of PASI after NB-UVB treatment (P <0.001) was observed and accompanied by decrease of the serum FABP5 (P=0.007). Conclusion: FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances and might be the missing link between psoriasis and metabolic disturbances.

Sign in / Sign up

Export Citation Format

Share Document